1. Home
  2. Nation
  3. ‘Covaxin’ for Children from 2-18 years commended by an expert panel

‘Covaxin’ for Children from 2-18 years commended by an expert panel

By Saima Siddiqui 
Updated Date
‘Covaxin’ for Children from 2-18 years commended by an expert panel

New Delhi: An expert panel on Tuesday commended Bharat Biotech’s Covid-19 vaccine, ‘Covaxin’, for use on children between the ages of two and 18.

Also Read :- Bengaluru doctor recovers from Omicron, tests Covid positive again after 2 weeks

Final approval will be given by the Drug Controller General of India. When that approval does come, Covaxin will be the second vaccine cleared for use on kids; in August Zydus Cadila’s three-dose DNA jab was allowed to be used on adults and children over 12.

A third potential vaccine for kids is Serum Institute’s Novavax, for which the DCGI last month cleared trials for children between seven and 11 years. A fourth is Biological E’s Corbevax, which has been cleared to conduct advanced trials on children above five.

Last week manufacturers Bharat Biotech said it had submitted all relevant data for vaccine trials on children between two and 18.

The Covaxin vaccine tested on children is the same formulation as used on adults, but separate trials were needed to guarantee safety and efficacy on younger recipients.

Also Read :- India records 6,822 new COVID-19 cases in 24 hours, lowest since May 2020

Data on these trials has not been made public yet, but tests were conducted on more than 1,000 children across the country.

India is slowly turning its focus towards vaccinating children against the coronavirus, having administered nearly 96 crore doses to adults.

Dr Randeep Guleria, chief of Delhi’s AIIMS, has stressed that children in the two-18 age group must be vaccinated “because that’s the only way to get rid of the pandemic”.

Earlier this month Dr NK Arora, the chief of India’s vaccine task force, told news agency ANI that children with severe comorbidities would be prioritised and that other (healthier) kids would be immunised subsequently.

“We are trying to identify (children) at highest risk… within the next couple of weeks, the list will be in the public domain. We are also making arrangements so these children do not have to travel (too far) to get the vaccine…” he said.

Also Read :- Covid-19: Indian airlines incurred losses of Rs 19,564 cr in 2020-’21: Centre

As schools re-open and students (and teaching and non-teaching staff) return to classrooms, concerns have been expressed over a spike in cases and the possibility of children being infected, as well as the need to also vaccinate adults working at schools.

India has so far fully vaccinated less than 30 crore of its 130 crore population.

Meanwhile, the World Health Organization has yet to grant Covaxin an EUA, or emergency use authorisation. Following delays in the process – the WHO had asked Bharat Biotech for additional trial data – a decision is expected next week.

Without an EUA, Covaxin will not be accepted as a valid COVID-19 vaccine by most countries around the world. This means Indians who received the jab will be forced to quarantine when travelling abroad, unlike those who received SII’s Covishield.

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...